Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 13/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL73946 | 0.92 | PRSS1 (0.55) | PRSS1F2PLAUST14 | |
| SCHEMBL13552192 | 0.89 | PRSS1 (0.52) | PRSS1F2PLAUST14 | |
| SCHEMBL13476052 | 0.88 | PRSS1 (0.52) | PRSS1F2PLAUST14 | |
| SCHEMBL74408 | 0.88 | LTB4R (0.43) | PRSS1 | |
| SCHEMBL6876936 | 0.84 | PRSS1 (0.47) | PRSS1F2PLAUST14 | |
| SCHEMBL13552209 | 0.79 | PRSS1 (0.55) | PRSS1F2PLAUST14 | |
| SCHEMBL73829 | 0.79 | MAPT (0.51) | — | |
| SCHEMBL13127138 | 0.77 | PRSS1 (0.61) | PRSS1F2PLAUST14 | |
| SCHEMBL12634447 | 0.77 | KCNH2 (0.44) | — | |
| SCHEMBL13127009 | 0.77 | PRSS1 (0.74) | PRSS1F2PLAUST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270807-A1 | MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| US-20120270769-A1 | METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA INC. (CA) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270769-A1 | METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | PRSS1, SPINT2, TMPRSS15 | PRSS1 1/4885F2 145/4885PLAU 88/4885 |
| US-20120270807-A1 | MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | PRSS1, SPINT2, SERPINB1 | PRSS1 1/4885F2 152/4885PLAU 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.